CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Charles River Laboratories International, Inc.
Equities
CRL
US1598641074
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 232.6 USD | -0.11% |
|
-1.16% | -1.62% |
Presenter SpeechSusan Hardy (Executives)Well, this is quiet. I guess we'll start now. Good mor...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows:
- discovery and safety assessment services (63.4%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides;
- development and sale of research models and related services (19.2%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ;
- development of solutions used in drug manufacturing processes (17.5%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies.
Net sales break down by source of income between sales of services (83.3%) and sales of products (16.7%).
Net sales are distributed geographically as follows: the United States (56.8%), Europe (26%), Canada (11.8%), Asia/Pacific (4.9%) and other (0.4%).
Calendar
30/07/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
232.6
USD
Average target price
265.6
USD
Spread / Average Target
+14.21%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.62% | 11.98B | |
| +29.77% | 49.46B | |
| +1.00% | 42.58B | |
| +50.47% | 42.49B | |
| -5.26% | 29.09B | |
| +13.68% | 26.61B | |
| -22.99% | 18.64B | |
| +8.22% | 13.16B | |
| +32.41% | 12.55B | |
| +24.01% | 12.1B |
- Stock Market
- Equities
- CRL Stock
- News Charles River Laboratories International, Inc.
- Transcript : Charles River Laboratories International, Inc. - Shareholder/Analyst Call
